 |
 Improving Thromboresistance and Patency of Vascular Grafts* 
|
 |
 |
Addressing the problem of thrombus formation on the luminal surface of a vascular graft is a challenge faced by all vascular surgeons.
The GORE PROPATEN Vascular Graft is specifically designed for those vascular procedures in which the risk of acute graft thrombotic failure is of clinical concern.
Anything better below-knee would be a vein
The GORE PROPATEN Vascular Graft harnesses the anticoagulant properties of heparin directly at the luminal surface of the graft. The proprietary end-point attachment mechanism serves to anchor heparin molecules to the luminal surface while still maintaining heparin’s intrinsic bioactive properties. The result: a thromboresistant BioActive graft surface that retains its bioactive properties over time.
The GORE PROPATEN Vascular Graft has demonstrated improved thromboresistance and patency compared to standard ePTFE grafts in pre-clinical in vivo tests. The thromboresistant surface technology employed on the GORE PROPATEN Vascular Graft is designed to maintain bioactivity over an extended time period, thus increasing the potential for sustained performance improvement and increased patency*.
*Long-term data are not available regarding improved patency compared to marketed grafts.